Quality Use of Medicines in Residential Aged Care

Total Page:16

File Type:pdf, Size:1020Kb

Quality Use of Medicines in Residential Aged Care RESEARCH Quality use of medicines in Michael Somers residential aged care Ella Rose Dasha Simmonds Claire Whitelaw Janine Calver Christopher Beer Background Approximately 190 000 people in high risk of ADEs in frail older people. For example, Older people are more likely to be Australia were estimated to have anticholinergic drugs commonly produce adverse exposed to polypharmacy. People dementia in 2006, with the prevalence effects in elderly people and are more likely to be with dementia, especially those living expected to increase to 465 000 by 2031.1 prescribed to people with dementia than those in residential aged care facilities The prevalence of dementia increases without.7 (RACFs), are at particularly high risk of with age, from 6.5% of Australians aged Antipsychotic medications are commonly used medication harm. We sought to describe medications prescribed for a sample of 65 years and over to 22% of Australians to manage the behavioural and psychological 2 people with dementia living in RACFs. aged 85 years and over. Dementia is symptoms of dementia (BPSD), such as associated with a large burden of disease psychosis, depression, agitation, aggression Methods in Australia’s aging population, costing and disinhibition.1,8 There is concern that A total of 351 residents with dementia Australia $1.4 billion in 2003.2 Most of this antipsychotics are used too frequently as a aged over 65 years were recruited from 36 RACFs in Western Australia. burden was associated with residential first line treatment for BPSD, with the risks of 2 Data on all medications prescribed aged care facilities (RACFs). Dementia antipsychotic use outweighing the benefits at their were collected, including conventional is the medical problem most frequently likely level of use.8 For example, risperidone, an medications, herbal medications, managed by general practitioners atypical antipsychotic prescribed frequently for the vitamins and minerals. attending RACFs.3 Ninety-six percent treatment of aggression, has been associated with 9 Results of people with dementia living in care increased risk of cerebrovascular adverse events. Polypharmacy was identified in accommodation in Australia have Recognised experts in clinical geriatric 91.2% (average 9.75 medications per moderate or severe dementia, compared care, clinical geriatric pharmacology, person); one-third were prescribed an to only 7% of people with dementia living pharmacoepidemiology and psychopharmacology antipsychotic medication; and 50.4% in households.1 Therefore people requiring have established the ‘Beers Criteria’, a list of were found to be taking at least one residential care tend to be among the potentially inappropriate medications (PIMs).10,11 potentially inappropriate medication. frailest and sickest in the community, This list was created using a consensus method, The combination of antipsychotics and with substantial physical and behavioural based on an extensive literature review and antidepressants was the most frequently needs and multiple comorbidities. questionnaire.10,11 The Beers Criteria identifies observed drug-drug interaction, being medications that should be avoided altogether, prescribed to 15.7% of participants. Polypharmacy, defined as the concurrent use of five as well as doses, frequencies and duration of Discussion or more medications, can result in an increased other medications that should be avoided in People with dementia living in RACFs are risk of drug-drug interactions (DDIs) and adverse the elderly.10,11 These medications have been commonly exposed to polypharmacy. drug events (ADEs).4 People with dementia are identified as being associated with higher medical Prescription of contraindicated at a higher risk of polypharmacy, with greater costs, increased rates of ADEs and poorer health medications, antipsychotics, medications increased risk as the disease progresses.5 A study outcomes.10,11 with high anticholinergic burden, and combinations of potentially inappropriate of Victorian RACFs found that one-third of drug A considerable number of people in RACFs mediations is also common. There related problems are caused by overprescribing, are exposed to dangerous DDIs, with one study may be substantial scope to improve including unnecessary drugs, duplication of therapy demonstrating that 60.2% of elderly inpatients were prescribing for older people with or inappropriate duration.6 Other causes of drug prescribed potential DDIs.7 The study participants dementia living in RACFs. related problems included dosing errors, suboptimal were most likely to be exposed to DDIs involving 6 Keywords: dementia; polypharmacy; drug monitoring, and underprescribing. Certain psychotropic medications, notably antipsychotics adverse effects classes of drugs are particularly associated with a with antidepressants, which can cause further Reprinted from AUstraLiaN FamiLY PHYsiciaN VOL. 39, No. 6, JUNE 2010 413 RESEARCH Quality use of medicines in residential aged care cognitive deterioration.7 The scope of potential DDIs, and antipsychotic and PIM use in Australia 11 736 165 has only been studied to a limited extent. Potential participants Did not meet criteria Australia’s National Medicines Policy highlights quality use of medicines as a central objective and the Australian Commission on 79 Safety and Quality in Health Care has been 571 Refused participation established to, in part, promote quality use of medicines.12 Despite this, the problem of ADEs persists.12 Prescribing to elderly people 141 is complicated by several factors including 492 Did not participate for changing pharmacokinetics with age, increased other reasons (eg. deceased, likelihood of multiple comorbidities, the need relocated, consent not obtained from next of kin) for polypharmacy to address these conditions, 351 and poor communication between health Eligible and willing to professionals.12–15 This results in an increased participate Figure 1. Participant recruitment likelihood of practitioners failing to adjust medication doses in the elderly, and to monitor and review their medications.12 Consequently, the participants were prescribed at the time of Research Ethics Committee of the University of medications can be used at incorrect doses, data collection, either as a regular or pro re nata Western Australia. for longer durations than clinically indicated, (PRN or ‘as required’) medication. Data on all when they are ineffective, and when an equally medications was collected, including conventional Results effective but safer alternative is available.12 medications as well as herbal medications, Of the 351 participants in the study, the mean This study aimed to describe the patterns of vitamins and minerals. age was 85.24 (SD: 7.87); 75.4% were female. prescribing for a sample of older people with The drug data was cleaned by removing The mean MMSE score was 12.50 (SD: 7.61). dementia living in RACFs, including: items that were not medications (eg. hearing Polypharmacy was identified in 320 • number of medications prescribed aid), removing duplicate drugs, correcting participants (91.2%). The number of medications • extent of psycholeptic use spelling errors, converting all drugs to generic taken by each participant ranged from 1 to 21 • use of potentially inappropriate medications names, and coding all drugs using the World (mean: 9.75, SD: 3.88). • drug-drug interactions Health Organization Anatomical, Therapeutic, One-hundred and seventeen (33.3%) of • anticholinergic burden. and Chemical (ATC) Classification System.16 the study participants were prescribed an The number of drugs was counted, with antipsychotic, with nine of these 117 being Methods polypharmacy defined as five or more drugs. The prescribed two antipsychotic medications A total of 351 people were included in the study number of psycholeptic (ATC code N05, including (Table 2). Risperidone, prescribed to 55 study (Figure 1). Inclusion criteria were: resident of a antipsychotics [N05A], anxiolytics [N05B] and participants, was the most commonly used Western Australian RACF; recorded diagnosis of hypnotics/sedatives [N05C]) and antidepressants antipsychotic. Other commonly prescribed dementia; age over 65 years; Mini-Mental State (N06A) were also counted. The modified Beers antipsychotics were quetiapine (prescribed to 22 Examination (MMSE) score of <24. Residents were Criteria were used to define PIMs (Table 1).10 participants), olanzapine (17 participants), and excluded if the facility staff identified them as A list of potential DDIs was compiled using haloperidol (15 participants). being acutely medically unstable or suffering from previously published data.7,17 The anticholinergic Fifty-five (15.7%) study participants were delirium, or in the terminal stages of dementia or a drug scale was used to determine anticholinergic prescribed a combination of antipsychotics and comorbid illness. burden.18,19 Using the scale, each medicine antidepressants. Consent for trial participation was sought was rated on a scale from 0–3 according to Potentially inappropriate medications were from the participant if able to give consent. their anticholinergic activity, with a rating of prescribed to 177 participants (50.4%). Of these Agreement for trial participation was also sought 0 indicating no anticholinergic potential and 3 participants, 115 (32.8%) were taking one from residents’ surrogates (next of kin or other indicating marked anticholinergic potential,18 and potentially inappropriate medication, 55 (15.7%) identified proxy) and the GP.
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • NIH Public Access Author Manuscript Pharmacol Ther
    NIH Public Access Author Manuscript Pharmacol Ther. Author manuscript; available in PMC 2010 August 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacol Ther. 2009 August ; 123(2): 239±254. doi:10.1016/j.pharmthera.2009.04.002. Ethnobotany as a Pharmacological Research Tool and Recent Developments in CNS-active Natural Products from Ethnobotanical Sources Will C. McClatcheya,*, Gail B. Mahadyb, Bradley C. Bennettc, Laura Shielsa, and Valentina Savod a Department of Botany, University of Hawaìi at Manoa, Honolulu, HI 96822, U.S.A b Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, U.S.A c Department of Biological Sciences, Florida International University, Miami, FL 33199, U.S.A d Dipartimento di Biologia dì Roma Trè, Viale Marconi, 446, 00146, Rome, Italy Abstract The science of ethnobotany is reviewed in light of its multidisciplinary contributions to natural product research for the development of pharmaceuticals and pharmacological tools. Some of the issues reviewed involve ethical and cultural perspectives of healthcare and medicinal plants. While these are not usually part of the discussion of pharmacology, cultural concerns potentially provide both challenges and insight for field and laboratory researchers. Plant evolutionary issues are also considered as they relate to development of plant chemistry and accessing this through ethnobotanical methods. The discussion includes presentation of a range of CNS-active medicinal plants that have been recently examined in the field, laboratory and/or clinic. Each of these plants is used to illustrate one or more aspects about the valuable roles of ethnobotany in pharmacological research.
    [Show full text]
  • Health and Social Outcomes Associated with High-Risk Alcohol Use
    Manitoba Centre for Health Policy Health and Social Outcomes Associated with High-Risk Alcohol Use Summer 2018 Nathan C Nickel, MPH, PhD Jeff Valdivia, MNRM, CAPM Deepa Singal, PhD James Bolton, MD Christine Leong, PharmD Susan Burchill, BMus Leonard MacWilliam, MSc, MNRM Geoffrey Konrad, MD Randy Walld, BSc, BComm (Hons) Okechukwu Ekuma, MSc Greg Finlayson, PhD Leanne Rajotte, BComm (Hons) Heather Prior, MSc Josh Nepon, MD Michael Paille, BHSc This report is produced and published by the Manitoba Centre for Health Policy (MCHP). It is also available in PDF format on our website at: http://mchp-appserv.cpe.umanitoba.ca/deliverablesList.html Information concerning this report or any other report produced by MCHP can be obtained by contacting: Manitoba Centre for Health Policy Rady Faculty of Health Sciences Max Rady College of Medicine, University of Manitoba 4th Floor, Room 408 727 McDermot Avenue Winnipeg, Manitoba, Canada R3E 3P5 Email: [email protected] Phone: (204) 789-3819 Fax: (204) 789-3910 How to cite this report: Nathan C Nickel, James Bolton, Leonard MacWilliam, Okechukwu Ekuma, Heather Prior, Jeff Valdivia, Christine Leong, Geoffrey Konrad, Greg Finlayson, Josh Nepon, Deepa Singal, Susan Burchill, Randy Walld, Leanne Rajotte, Michael Paille. Health and Social Outcomes Associated with High-Risk Alcohol Use. Winnipeg, MB. Manitoba Centre for Health Policy, Summer 2018. Legal Deposit: Manitoba Legislative Library National Library of Canada ISBN 978-1-896489-90-2 ©Manitoba Health This report may be reproduced, in whole or in part, provided the source is cited. 1st printing (Summer 2018) This report was prepared at the request of Manitoba Health, Seniors and Active Living (MHSAL), a department within the Government of Manitoba, as part of the contract between the University of Manitoba and MHSAL.
    [Show full text]
  • Ambulanter) Pflege (Mupp
    Multimedikation bei älteren Patienten mit (ambulanter) Pflege (MuPP) Gefördert mit Mitteln des LZG.NRW AutorInnen Dr. Veronika Lappe Peter Ihle Dr. Ingrid Schubert Ansprechpartner Dr. Ingrid Schubert, Tel. 0221-478-6545 [email protected] PMV forschungsgruppe Ltg. Dr. I. Schubert Klinik und Poliklinik für Kinder- und Jugendpsychiatrie der Universität zu Köln Herderstraße 52 50931 Köln www.pmvforschungsgruppe.de Mitgliedseinrichtung des Zentrums für Versorgungsforschung Köln (Sprecher Prof. Dr. H. Pfaff) Förderung Die Studie wurde mit Mitteln vom Landeszentrum Gesundheit Nordrhein-Westfalen (AZ34.1.2-GC 05/13) gefördert. Danksagung Die Autoren danken der »AOK NORDWEST – Die Gesund- heitskasse« und der »AOK Rheinland/Hamburg – Die Gesundheitskasse« für die Datenbereitstellung. Hinweis Im Bericht wird aus Gründen der besseren Lesbarkeit für Berufsgruppenbezeichnungen sowie für Patienten und Patientinnen die männliche Form benutzt, die jedoch Frauen wie Männer in gleicherweise mit einschließt. Köln, Februar 2015 Copyright 2015 PMV forschungsgruppe Multimedikation bei Pflege Landeszentrum Gesundheit NRW II In Inhaltsverzeichnis 1 Einleitung 1 1.1 Kontext der Untersuchung 1 1.2 Ziel der Untersuchung 3 2 Material und Methodik 4 2.1 Datenbasis 4 2.2 Studienpopulation 5 2.3 Datenaufbereitung und Definitionen 6 2.3.1 Pflegedaten 6 2.3.2 Arzneimittelverordnungen 6 2.3.3 Definition von Multimedikation 8 2.3.4 Art der Multimedikation 8 2.3.5 Regionale Differenzierung 13 2.4 Verwendete Software und statistische Methoden 14 3 Ergebnisse 15 3.1
    [Show full text]
  • PHRP March 2015
    March 2015; Vol. 25(2):e2521518 doi: http://dx.doi.org/10.17061/phrp2521518 www.phrp.com.au Research Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study Danijela Gnjidica,b,i, Sallie-Anne Pearsona,c, Sarah N Hilmerb,d, Jim Basilakise, Andrea L Schaffera, Fiona M Blythb,f,g and Emily Banksg,h, on behalf of the High Risk Prescribing Investigators a Faculty of Pharmacy, University of Sydney, NSW, Australia b Sydney Medical School, University of Sydney, NSW, Australia c Sydney School of Public Health, University of Sydney, NSW, Australia d Royal North Shore Hospital and Kolling Institute of Medical Research, Sydney, NSW, Australia e School of Computing, Engineering and Mathematics, University of Western Sydney, NSW, Australia f Centre for Education and Research on Ageing (CERA), Concord Hospital, Sydney, NSW, Australia g The Sax Institute, Sydney, NSW, Australia h National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT i Corresponding author: [email protected] Article history Abstract Publication date: March 2015 Background: Increasingly, automated methods are being used to code free- Citation: Gnjidic D, Pearson S, Hilmer S, text medication data, but evidence on the validity of these methods is limited. Basilakis J, Schaffer AL, Blyth FM, Banks E. To examine the accuracy of automated coding of previously keyed Manual versus automated coding of free-text Aim: in free-text medication data compared with manual coding of original self-reported medication data in the 45 and Up Study: a validation study. Public Health handwritten free-text responses (the ‘gold standard’).
    [Show full text]
  • Plant Powers, Poisons, and Herb Craft
    PLANT POWERS, POISONS, AND HERB CRAFT BY DALE PENDELL Foreword by Gary Snyde, $21.95 US In 'Pharmako/Poeia, Dale Pendell offers a mesmerizing guide to psychoactive Alternative plants, from their pharmacological roots to the literary offshoots. "This is a Health/ book," writes Gary Snyder, "about danger: dangerous knowledge, even more Literature dangerous ignorance." Against the greater danger, ignorance, Pendell strikes a formidable blow, as he proves himself a wise and witty guide to our plant teach- ers, their powers and their poisons. "Dale Pendell reactivates the ancient connection between the bardic poet and the shaman. His Pharmako/Poeia is a litany to the secret plant allies that have always accompanied us along the alchemical trajectory that leads to a new and yet authentically archaic future." — Terence McKenna, author of True Hallucinations "Much of our life-force calls upon the plant world for support, in medicines and in foods, as both allies and teachers. Pendell provides a beautifully crafted bridge between these two worlds. The magic he shares is that the voices are spoken and heard both ways; we communicate with plants and they with us. This book is a moving and poetic presentation of this dialogue." — Dr. Alexander T. Shulgin, University of California at Berkeley, Department of Public Health "Pharmako/Poeia is an epic poem on plant humours, an abstruse alchemic treatise, an experiential narrative jigsaw puzzle, a hip and learned wild-nature reference text, a comic paean to cosmic consciousness, an ecological handbook, a dried-herb pastiche, a countercultural encyclopedia of ancient fact and lore that cuts through the present 'conservative' war-on-drugs psychobabble." - Allen Ginsberg, poet Cover design "Dale PendelFs remarkable book will make it impossible to and color work ever again underestimate the most unprepossessing plant.
    [Show full text]
  • Development of a Multivariable Prediction Model for Identification of Patients at Risk for Medication Transfer Errors at ICU Discharge
    RESEARCH ARTICLE Development of a multivariable prediction model for identification of patients at risk for medication transfer errors at ICU discharge 1,2 1,3 2,4 Liesbeth B. E. BosmaID *, Nienke van Rein , Nicole G. M. Hunfeld , Ewout W. Steyerberg5, Piet H. G. J. Melief6, Patricia M. L. A. van den Bemt2 1 Haga Teaching Hospital, Department of Clinical Pharmacy, Els Borst-Eilersplein CH, The Hague, The Netherlands, 2 Erasmus University Medical Center, Department of Hospital Pharmacy, CA, Rotterdam, The Netherlands, 3 Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands, 4 Erasmus University Medical Center, Department of Intensive Care, CA, Rotterdam, The a1111111111 Netherlands, 5 Clinical Biostatistics and Medical Decision Making at Erasmus MC, Rotterdam and Leiden a1111111111 University Medical Center, ZA Leiden, The Netherlands, 6 Haga Teaching Hospital, Department of Intensive Care, CH, The Hague, The Netherlands a1111111111 a1111111111 * [email protected] a1111111111 Abstract OPEN ACCESS Introduction Citation: Bosma LBE, van Rein N, Hunfeld NGM, Steyerberg EW, Melief PHGJ, van den Bemt PMLA Discharge from the intensive care unit (ICU) is a high-risk process, leading to numerous (2019) Development of a multivariable prediction potentially harmful medication transfer errors (PH-MTE). PH-MTE could be prevented by model for identification of patients at risk for medication reconciliation by ICU pharmacists, but resources are scarce, which renders the medication transfer errors at ICU discharge. PLoS ONE 14(4): e0215459. https://doi.org/10.1371/ need for predicting which patients are at risk for PH-MTE. The aim of this study was to journal.pone.0215459 develop a prognostic multivariable model in patients discharged from the ICU to predict who Editor: Shane Patman, University of Notre Dame is at increased risk for PH-MTE after ICU discharge, using predictors of PH-MTE that are Australia, AUSTRALIA readily available at the time of ICU discharge.
    [Show full text]
  • Development of the Medicines Optimisation Assessment Tool (MOAT)
    Department of Practice and Policy UCL School of Pharmacy PhD Thesis – University College London Development of the Medicines Optimisation Assessment Tool (MOAT) Targeting hospital pharmacists' input to reduce risks and improve patient outcomes Cathy Anne Geeson NIHR Clinical Doctoral Research Fellow Pharmacy Department Luton and Dunstable University Hospital 1 Declaration I, Cathy Geeson confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signature: Date: 2 Abstract Abstract Background Medicines optimisation is a key role for hospital pharmacists, but with ever-increasing demands on services, there is a need to increase efficiency while maintaining patient safety. The aim of this study was to use prognostic modelling to develop a prediction tool, the Medicines Optimisation Assessment Tool (MOATTM), to target patients most in need of pharmacists’ input while in hospital. Methods and analysis Patients from adult medical wards at two UK hospitals were prospectively included into this cohort study between April and November 2016. Data on medication related problems (MRPs) were collected by pharmacists at the study sites as part of their routine daily clinical assessment of patients. Data on potential risk factors, such as polypharmacy and use of ‘high-risk’ medicines, were collected retrospectively from the information departments at the study sites, laboratory reporting systems and patient medical records. Multivariable logistic regression was used to determine the relationship between potential risk factors and the study outcome, namely preventable MRPs that were at least moderate in severity. A simplified electronic scoring system (the MOAT) was then developed.
    [Show full text]
  • Online Appendix
    The More We Die, The More We Sell? A Simple Test of the Home-Market Effect Online Appendix Arnaud Costinot Dave Donaldson MIT, CEPR, and NBER MIT, CEPR, and NBER Margaret Kyle Heidi Williams Mines ParisTech and CEPR MIT and NBER December 28, 2018 1 Contents A Theoretical Appendix3 A.1 Multinational Enterprises (Section III.1)..........................3 A.2 Log-Linearization (Section III.2)...............................3 A.3 Beyond Perfect Competition (Section III.3).........................6 A.3.1 Monopolistic Competition..............................6 A.3.2 Variable Markups...................................7 A.3.3 Endogenous Innovation...............................8 A.3.4 Price Regulations...................................9 A.4 Bilateral Sales (Section VI.1)................................. 12 B Empirical Appendix 12 B.1 Rich versus Poor Countries................................. 12 B.2 Additional Empirical Results................................ 13 B.3 Benchmarking IMS MIDAS data.............................. 13 B.3.1 Benchmarking to the OECD HealthStat Data................... 13 B.3.2 Benchmarking to the MEPS Data.......................... 14 B.4 ATC to GBD Mapping.................................... 15 2 A Theoretical Appendix A.1 Multinational Enterprises (Section III.1) In this appendix, we illustrate how to incorporate multinational production into our basic envi- ronment. Following Ramondo and Rodríguez-Clare(2013), suppose that each firm headquartered in country i that sells drugs targeting disease n in country j 6= i can choose the country l in which its production takes place. If l = i, then the firm exports, if l = j, it engages in horizontal FDI, and if l 6= i, j, it engages in platform FDI. Like in Ramondo and Rodríguez-Clare(2013), we assume that firm-level production functions exhibit constant returns to scale, but we further allow for external economies of scale at the level of the headquarter country for each disease.
    [Show full text]
  • Health Effects of Labor Market Policies: Evidence from Drug Prescriptions
    Health Effects of Labor Market Policies: Evidence from Drug Prescriptions Marco Caliendo∗ Robert Mahlstedty Gerard J. van den Bergz teststets Johan Vikstr¨omx Preliminary Version This draft: November 13, 2019 -Please do not cite or circulate- We exploit individual-level labor market and prescription drug records to study unintended effects of labor market policies on participants' health status. We examine two popular and commonly used interventions that represent different reintegration strategies for unemployed workers: training programs and benefit sanctions. To establish a causal relationship we ex- ploit the longitudinal aspect of the prescription records and estimate dynamic difference- in-differences models comparing treated and non-treated individuals before and after the treatment. Our results show that supportive interventions, such as training programs, re- duce drug prescriptions related to cardiovascular and mental health diseases by about 6-7% within a year after the program start. The direct effect of participating, e.g. due to a change of daily routines, seem to be more important than the indirect effect through improved em- ployment prospects. Restrictive interventions, such as benefit sanctions, have no long-lasting effects on drug prescriptions, but the notification of an upcoming sanction leads to a short- term increase in prescriptions for mental health issues, which is possible induced by higher stress levels. Keywords: Unemployment, Labor market policies, Health Effects JEL codes: J68, I12, I18, H51 ∗University of Potsdam, IZA Bonn, DIW Berlin, IAB Nuremberg; [email protected] yUniversity of Copenhagen and IZA Bonn; [email protected] Corresponding address: University of Copenhagen, Department of Economics, Øster Farimagsgade 5, 1353 Copen- hagen K, Denmark.
    [Show full text]
  • BULGARIA New Development, Trends and In-Depth Information on Selected Issues
    2007 NATIONAL REPORT (2006 data) TO THE EMCDDA by the Reitox National Focal Point BULGARIA New Development, Trends and in-depth information on selected issues REITOX 1 TABLES OF CONTENTS Summary..........................................................................................................................3 Part A: New Trends and Developments 1. National Policies and Context ......................................................................................8 2. Drug use in the General Population and Specific Sub-groups ...................................21 3. Prevention ..................................................................................................................29 4. Problem Drug Use......................................................................................................39 5. Drug-Related Treatment.............................................................................................47 6. Health Correlates and Consequences........................................................................51 7. Responses to Health Correlates and Consequences.................................................65 8. Social correlates and consequences..........................................................................72 9. Response to social correlates and consequences .....................................................82 10. Drug Markets............................................................................................................88 Part B: Selected issues 12. Vulnerable Groups of
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]